# A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Source: https://onco.cc/trials/nct06943521/  
OnCo record `nct06943521` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MT-4561 in head and neck squamous cell carcinoma, non-small-cell lung cancer, oesophageal cancer, gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, run by Tanabe Pharma America, Inc., now recruiting.

## Summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06943521 by Tanabe Pharma America, Inc., with 27 participants planned, started 2025-04-18 and due to reach its primary completion in 2028-08. Interventions recorded: MT-4561.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06943521
- Phase: 1/2
- Setting: A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam
- Sponsor: Tanabe Pharma America, Inc.
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT06943521: https://clinicaltrials.gov/study/NCT06943521

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct06943521.json